Crossmark forms Crossmark Drug and Value business unit
PLANO, Texas — Crossmark has added a new business unit to its sales agency.
The sales and marketing services company said Crossmark Drug and Value — a unit consisting of Crossmark MPG Drug and Crossmark Value — is dedicated to providing growth solutions for manufacturer and retailer clients in the drug and value channels.
In line with the formation of the unit, the company appointed Alex Yakulis to serve as VP, general manager.
“Crossmark will provide strategic headquarter and analytical support to assist clients in achieving their desired outcomes,” Yakulis said. “This will be complemented by retail merchandising support at more than 40,000 retail locations in these two channels.”
That's really a great news Crossmark have really increased their business and reached at every part, and all their retailers have also been in part to help them and expand their business,and i am on of it online medical assistant courses and it great to be a part of such a unit.
Well deserved achievement for Alex - he's one of this industry's true leaders. Best wishes in the new venture.
FDA approves Hi-Tech Pharmacal’s anxiety drug
AMITYVILLE, N.Y. — The Food and Drug Administration has approved a generic drug for anxiety made by Hi-Tech Pharmacal, the drug maker said Tuesday.
The FDA approved Hi-Tech’s lorazepam oral concentrate in the 2-mg-per-mL strength, a generic version of Roxanne Labs’ Intensol.
Branded and generic versions of the drug had sales of $10 million in 2011, according to IMS Health.
No comments found
PDUFA reauthorization goals draw support from NACDS
ALEXANDRIA, Va. — A goal to standardize risk evaluation and mitigation strategies and modernize the U.S. drug safety system in a proposed reauthorization of the Prescription Drug User Fee Act has drawn support from the country’s main chain retail pharmacy lobby.
The National Association of Chain Drug Stores submitted written testimony Tuesday ahead of a congressional hearing on the reauthorization of PDUFA, originally enacted in 1992.
Specifically, the group endorsed its goals to have the Food and Drug Administration review drug applications for similarity in drug brand names that could result in medication errors and integrate REMS programs into the healthcare delivery system. The testimony also highlighted such policies as medication therapy management and cracking down on illegal sales of drugs on the Internet.
"We believe that REMS should be subject to review by pharmacies and other relevant healthcare providers, such as by a representative panel of expert reviewers to include pharmacists who practice in pharmacy settings affected by the REMS," the testimony read. "Although pharmacies are not directly responsible to FDA for the design, implementation and success of REMS, pharmacies are subject to the elements of REMS in order to meet the needs of their patients."
No comments found